Fair-skinned people - who traditionally burn the most in the sun - benefited most from an anti-sunburn drug which has finished Phase II human trials, the Professor of Dermatology at Sydney University said today.
Professor Ross Barnetson - a world authority in the field of photobiology, ultraviolet skin damage and the immunology of skin tumours - ran the Phase II human trials at Sydney University, alongside a concurrent trial at Royal Adelaide Hospital. Eighty volunteers took part in the trial.
Results of the trial into the drug Melanotan - which stimulates the production of melanin in the skin - showed that:
"The aim of the trial was to determine how Melanotan could reduce the degree and toxicity of sunburn in 80 healthy volunteers exposed to ultraviolet light both before and after a regime of the drug," said Professor Barnetson. "The fair-skinned people who took Melanotan had half the skin damage after the study compared to before the study. The results showed that fair-skinned people who have developed a tan are less likely to burn."
The drug was administered daily for ten days in each of three consecutive months. Twenty volunteers received placebos. The volunteers, of varying skin types, received controlled levels of UVA and UVB radiation onto a small area of skin resulting in a level of burning similar to spending 30-120 minutes in strong sun without sunscreen. A skin biopsy was taken from each to measure the level of resulting sunburn injury. The volunteers then received a regime of Melanotan, the same UV radiation exposure, and another skin biopsy.
A volunteer in the trial, Rachel Preece, a 25-year-old medical student, said that the drug gave her an even, all-over tan. She said she recognised the protective elements of the tan. "I am not a sun-lover and don’t go on the beach often. Being a medical student I see a lot of bad effects of sun-baking with skin cancers. I would take this drug if it was commercialised."
Professor Alan Cooper, Head of the Department of Dermatology at Sydney’s Royal North Shore Hospital, said: "I think its reasonable that we can consider Melanotan to be an internal sunscreen. Melanin is the body’s natural sunscreen and this is a way of increasing the amount of melanin we have."
Dr Wayne Millen, Managing Director of EpiTan - the biotechnology company developing Melanotan - said he was delighted with the results. "The results improve our chances of commercialising the world’s first prescription sunscreen. There is no other product available today to prevent sunburn apart from sunscreen. We expect Melanotan to be especially beneficial to those people with fair skin types who are most at risk of sunburn injury and therefore of developing skin cancers."
EpiTan recently announced that, following a successful meeting with the United States Food & Drug Administration, it would lodge an Investigational New Drug application in mid-2004. Clinical trials for a newly-developed long-acting implant has begun at Q-Pharm in Queensland. This trial is expected to conclude in May 2004.
For more information contact:
Professor Ross Barnetson, Sydney University, 02 9515-6861
Mr Iain Kirkwood, Chief Administrative Officer, EpiTan Limited, Tel: 03 9662-4688 or 0408 473 496
Mr Richard Allen, Monsoon Communications, Tel: 03 9620-3333 or 0403 493 049
Rebecca Piercey | Monsoon Communications
The genes are not to blame
20.07.2018 | Technische Universität München
Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz
A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.
The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
20.07.2018 | Power and Electrical Engineering
20.07.2018 | Information Technology
20.07.2018 | Materials Sciences